Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Aktis Oncology in a report released on Friday, November 13th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings per share of ($1.97) for the year, down from their prior forecast of ($1.64). The consensus estimate for Aktis Oncology's current full-year earnings is ($1.86) per share. HC Wainwright also issued estimates for Aktis Oncology's Q4 2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.73) EPS and FY2027 earnings at ($2.73) EPS.
Aktis Oncology (NASDAQ:AKTS - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The technology company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.07). The company had revenue of $3.91 million for the quarter, compared to analysts' expectations of $4.87 million.
A number of other analysts have also recently issued reports on AKTS. Weiss Ratings cut Aktis Oncology from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday. BMO Capital Markets began coverage on Aktis Oncology in a research report on Tuesday, August 18th. They set an "outperform" rating and a $37.00 price target on the stock. Wall Street Zen lowered Aktis Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. Oppenheimer started coverage on Aktis Oncology in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $40.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and issued a $35.00 price objective on shares of Aktis Oncology in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aktis Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.62.
Get Our Latest Research Report on Aktis Oncology
Aktis Oncology Stock Down 2.8%
Shares of AKTS stock opened at $16.16 on Tuesday. The stock's 50-day moving average is $18.32 and its two-hundred day moving average is $20.77. Aktis Oncology has a 1 year low of $13.96 and a 1 year high of $34.19.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of AKTS. GK Wealth Management LLC acquired a new stake in shares of Aktis Oncology during the third quarter worth about $26,000. Silver Grove Financial Group Inc. acquired a new position in Aktis Oncology in the 3rd quarter valued at about $28,000. Global Retirement Partners LLC increased its position in Aktis Oncology by 289.1% in the 3rd quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company's stock valued at $30,000 after acquiring an additional 1,142 shares during the period. State of Wyoming purchased a new stake in Aktis Oncology during the 2nd quarter valued at approximately $32,000. Finally, Aquatic Capital Management LLC purchased a new stake in Aktis Oncology during the 3rd quarter valued at approximately $77,000. 28.84% of the stock is currently owned by institutional investors and hedge funds.
About Aktis Oncology
(
Get Free Report)
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company's pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aktis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aktis Oncology wasn't on the list.
While Aktis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.